New CFO brings more than 15 years of experience in financial leadership roles
SOUTH RIDING, Va., April 26, 2022 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Richard B. Bartram as Chief Financial Officer (CFO) at MBX Biosciences, a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine disorders.
Bartram is an accomplished and experienced financial executive with an extensive understanding of the capital markets and a wide variety of experience in private transactions, initial public offerings, follow-on equity offerings, debt offerings, and other financial transactions. He previously served as CFO at Esperion Therapeutics where he led the company's successful efforts to raise more than $1.2 billion in capital to support the approval and commercialization of two of the company's cholesterol drugs. Prior to his tenure at Esperion, Bartram served as an assurance manager with PricewaterhouseCoopers LLP.
"Rick Bartram is a tremendously talented and respected business leader with an outstanding track record of success over many years," said Slone Partners CEO Leslie Loveless. "He is a savvy financial strategist, operational planner, and trusted business partner, and will be a wonderful addition to the MBX executive team."
"I am delighted to welcome Rick to the MBX leadership team as our CFO and look forward to benefitting from his financial acumen as we strive to advance our innovative pipeline of programs aimed at the development of new medicines for patients with endocrine disorders," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "He has the experience, and the right financial and business skill set to be a driving force in our future growth."
"I am thrilled to join MBX Biosciences at such an exciting time of opportunity for the company," said Bartram. "I look forward to helping the company reach its strategic and financial objectives as it develops innovative medicines for the patients who need them."
Bartram earned his undergraduate and graduate degrees in Accounting from Michigan State University and is a Certified Public Accountant.
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.
ABOUT MBX BIOSCIENCES
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company's lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX's leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed. For more information, please visit http://www.mbxbio.com or follow-us on LinkedIn.
Media Contact
Doug Gavel, Doug Gavel Communications, (617) 429-4417, [email protected]
SOURCE Slone Partners
Share this article